DocWire News Editors

DocwireNews

Researchers evaluated the onset of action of the monoclonal antibody benralizumab by assessing changes in morning peak expiratory flow (PEF).&nbsp;Geoffrey Chupp, MD,&nbsp;of the Yale Center for Asthma and Airway Disease in New Haven, Connecticut, and colleagues found that benralizumab produced rapid and sustained increases in morning PEF in patients with severe, uncontrolled eosinophilic asthma. The results were presented at the 2018 AAAAI Annual Meeting.They used data from the phase III SIROCCO and CALIMA trials to identify patients &ge;12 years old who were receiving high-dose inhaled corticosteroid/long-acting beta-agonists with baseline blood eosinophils &ge;300 cells/mL.Patients in the 48-week SIROCCO and 56-week CALIMA trials received:<ul>
<li>Benralizumab 30 mg every 8 weeks (every 4 weeks for the first 3 doses; SIROCCO, n=267; CALIMA, n=239)</li>
<li>Placebo (SIROCCO, n=267; CALIMA, n=248)</li>
</ul>In this post-hoc analysis, the researchers assessed patients&rsquo; average weekly changes in morning PEF from baseline to end of treatment.Compared with placebo, benralizumab increased the mean morning PEF changes by 22.74 L/min (95% confidence interval [CI], 21.25-24.20) in the SIROCCO study and by 23.73 L/min (95% CI, 22.52-24.99) in the CALIMA study.The researchers observed differences in mean PEF changes from baseline during the first week among those treated with benralizumab versus placebo for both trials:<ul>
<li>SIROCCO: 14.05 L/min (95% CI, 13.16-14.96) vs 7.16 L/min (95% CI, 6.28-7.99)</li>
<li>CALIMA: 14.58 L/min (95% CI, 13.71-15.83) vs 8.75 L/min (95% CI, 7.91-9.65)</li>
</ul>The mean time to achieve a 25 L/min increase in morning PEF with benralizumab was 20.7 days in the SIROCCO trial (95% CI 19.3-22.1) and 20.0 days in the CALIMA trial (95% CI 18.6-21.7). Those receiving placebo did not achieve a 25 L/min increase in either trial.Source: Chupp G, Ferguson GT, Hirsch I, et al. Benralizumab treatment produces rapid changes in morning peak expiratory flow in patients with severe, uncontrolled eosinophilic asthma. Abstract #44. Presented at the 2018 AAAAI Annual Meeting, March 2-5, 2018, Orlando, FL.

Roger Rodby, MD

Joel M. Topf, MD, FACP

Seldin Award Winner Advocates Online Education

NKF Spring Clinical Meetings 2025

Hatem Soliman, MD

The Future of Dendritic Cell Vaccines in HER2+ Breast Cancer: Toward De-Escalation of Chemotherapy

HER2 Breast Cancer

Jordana Jampel

Mechanism of Positive Association Between Parkinson’s Disease and Melanoma Revealed in New Research

Melanoma

Latest News

Benralizumab Increases Morning PEF in Patients with Eosinophilic Asthma

AAAAI 2018

Researchers evaluated the onset of action of the monoclonal antibody benralizumab by assessing changes in morning peak expiratory flow (PEF). Geoffrey Chupp, MD, of the Yale ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe